Preclinical Investigation of ²¹²Pb-DOTAMTATE for Peptide Receptor Radionuclide Therapy in a Neuroendocrine Tumor Model.

ABSTRACT: Somatostatin analogues have been examined as a treatment for somatostatin receptor overexpressing tumors for years; specifically, octreotate (TATE) and octreotide (TOC). Several versions of these analogues coupled to beta or gamma nuclides are currently used as imaging agents, as treatments with peptide receptor radionuclide therapy (PRRT) for patients with neuroendocrine tumors or are being explored in preclinical and clinical settings. Our study describes the use of ²¹²Pb-DOTAMTATE, the octreotate analogue, in combination with ²¹²Pb, the parent of an alpha emitter. Preclinical studies demonstrated tumor targeting of ²¹²Pb-DOTAMTATE of >20% ID/g up to 24 hours post drug injection. The addition of kidney protection agents, including l-lysine and l-arginine

SUBMITTER: Stallons TAR 

PROVIDER: S-EPMC6497546 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature